IL33 and neoplasm: Overexpression of active IL33 in tumor cells, administration of IL33 protein, as well as checkpoint inhibitor-induced tumor cell-derived IL33 inhibited tumor growth in multiple tumor models (Gao et al., 2015; Dominguez et al., 2017; Hollande et al., 2019; Chen et al., 2020; Moral et al., 2020).